Assetmark Inc. boosted its holdings in shares of Humana Inc. (NYSE:HUM - Free Report) by 19.4% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 14,723 shares of the insurance provider's stock after buying an additional 2,392 shares during the period. Assetmark Inc.'s holdings in Humana were worth $4,663,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Several other hedge funds also recently added to or reduced their stakes in HUM. Envestnet Portfolio Solutions Inc. increased its position in Humana by 137.6% during the 1st quarter. Envestnet Portfolio Solutions Inc. now owns 4,801 shares of the insurance provider's stock valued at $1,665,000 after buying an additional 2,780 shares in the last quarter. Sei Investments Co. increased its holdings in shares of Humana by 0.4% in the first quarter. Sei Investments Co. now owns 61,897 shares of the insurance provider's stock valued at $21,462,000 after purchasing an additional 264 shares during the period. Avantax Advisory Services Inc. increased its holdings in shares of Humana by 11.2% in the first quarter. Avantax Advisory Services Inc. now owns 2,721 shares of the insurance provider's stock valued at $943,000 after purchasing an additional 275 shares during the period. ProShare Advisors LLC increased its holdings in shares of Humana by 3.4% in the first quarter. ProShare Advisors LLC now owns 19,962 shares of the insurance provider's stock valued at $6,921,000 after purchasing an additional 658 shares during the period. Finally, BNP PARIBAS ASSET MANAGEMENT Holding S.A. increased its holdings in shares of Humana by 356.0% in the first quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 87,939 shares of the insurance provider's stock valued at $30,490,000 after purchasing an additional 68,655 shares during the period. 92.38% of the stock is owned by institutional investors and hedge funds.
Analyst Ratings Changes
A number of brokerages have recently weighed in on HUM. Sanford C. Bernstein raised Humana from a "market perform" rating to an "outperform" rating and set a $308.00 price objective on the stock in a report on Tuesday, October 8th. Truist Financial lowered their target price on Humana from $400.00 to $260.00 and set a "hold" rating on the stock in a research note on Friday, October 11th. Oppenheimer lowered their target price on Humana from $400.00 to $280.00 and set an "outperform" rating on the stock in a research note on Thursday, October 3rd. Royal Bank of Canada lowered their target price on Humana from $400.00 to $265.00 and set an "outperform" rating on the stock in a research note on Tuesday, October 8th. Finally, Stephens restated an "equal weight" rating and issued a $250.00 target price on shares of Humana in a research note on Wednesday, October 9th. Twenty equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company. Based on data from MarketBeat, Humana currently has an average rating of "Hold" and an average price target of $315.86.
Check Out Our Latest Analysis on HUM
Humana Stock Performance
Shares of HUM stock traded up $9.36 during trading hours on Wednesday, reaching $289.42. 2,158,046 shares of the company's stock were exchanged, compared to its average volume of 1,874,213. The company has a market cap of $34.85 billion, a P/E ratio of 25.64, a price-to-earnings-growth ratio of 2.21 and a beta of 0.52. The company's 50 day moving average is $286.27 and its two-hundred day moving average is $332.44. Humana Inc. has a 1 year low of $213.31 and a 1 year high of $527.18. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.76 and a quick ratio of 1.76.
Humana (NYSE:HUM - Get Free Report) last released its quarterly earnings data on Wednesday, October 30th. The insurance provider reported $4.16 earnings per share for the quarter, beating the consensus estimate of $3.48 by $0.68. Humana had a return on equity of 13.20% and a net margin of 1.18%. The firm had revenue of $29.30 billion during the quarter, compared to the consensus estimate of $28.66 billion. Equities research analysts anticipate that Humana Inc. will post 15.83 EPS for the current fiscal year.
Humana Dividend Announcement
The company also recently disclosed a quarterly dividend, which will be paid on Friday, January 31st. Investors of record on Tuesday, December 31st will be paid a $0.885 dividend. This represents a $3.54 annualized dividend and a yield of 1.22%. The ex-dividend date is Tuesday, December 31st. Humana's payout ratio is currently 31.36%.
About Humana
(
Free Report)
Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.
See Also
Before you consider Humana, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Humana wasn't on the list.
While Humana currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
